ClinicalTrials.gg
CompletedNCT04038047PROMISEUpdated Jan 28, 2025

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

An observational study in Cystic Fibrosis, sponsored by Nicole Hamblett. Completed at 56 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Nicole Hamblett · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
490
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
29th of 193
490 · median 80
Started
2019
with 38 others
Observational
194 of 717
41 open now
Registered
511th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 29th largest by enrollment of the 193 observational ones that give a count, is one of 39 that started in 2019, is one of 194 observational ones, and was the 511th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in people with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before TCT" visit within 30 days before initiation of the therapy and five "after TCT" visits over a 30-month follow-up period. Participants who have participated in the original PROMISE cohort have the option of participating in a long-term extension with annual visits performed at the 42- and 54-month timepoints. The durability of the clinical and biological changes in PROMISE can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. Most participating sites have been divided into sub-study groups; each sub-study group has specific non-optional procedures conducted in addition to the "Core" procedures. Finally, there is one optional procedure (transient elastography) that will be offered to subjects at certain sites. The duration of participation for each subject is 30 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has reviewed the New Drug Application (NDA) for elexacaftor, tezacaftor and ivacaftor and has granted approval.

Read the detailed description

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In people with CF, this manifests as dysfunction in multiple organ systems including the lungs, pancreas, liver, intestines, skin and others.

While nearly 2000 mutations have been described, the most common disease-causing CFTR mutation is F508del, which is found in >85% of patients followed in the US CF Patient Registry. Two CFTR corrector drugs plus the potentiator ivacaftor have been developed as a triple combination therapy for CF patients with one or two copies of the F508del mutation. We predict that over 90% of CF patients (initially age 12 y/o and above) will be eligible for highly effective CFTR modulator therapy in the U.S.

The PROMISE study is designed to measure the direct and indirect CFTR-dependent anion secretion by collecting and analyzing clinical research outcomes and biomarkers on a large number of patients both before and after they begin treatment with elexacaftor, tezacaftor and ivacaftor triple combination therapy (TCT). This study will investigate the impact of TCT across a wide range of CF disease manifestations and organ systems. While specific biomarkers of special interest have been selected for detailed analysis in this study, an additional important goal is to collect blood, urine, stool, and airway epithelial cell specimens for long-term storage in a biorepository to enable future research. These samples can be made available for research beyond the current scope of work. The PROMISE study will provide a coordinated collection of clinical research outcomes data that can be linked with these specimens.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • CF
  • CFTR modulator
  • triple combination therapy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with Cystic Fibrosis, prescribed the elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All genders within the age limit of the FDA approved indication for elexacaftor, tezacaftor and ivacaftor triple combination therapy (TCT) at Day 1.
  2. Diagnosis of CF.
  3. CFTR mutations consistent with the FDA approved indication for elexacaftor, tezacaftor and ivacaftor triple combination therapy (TCT).
  4. Physician intent to prescribe elexacaftor, tezacaftor and ivacaftor triple combination therapy (TCT).
  5. Willing to fast for 8 hours prior to all study visits (for subjects on overnight enteric tube feedings, willing to hold the feeding for at least 8 hours).
  6. Able to perform the testing and procedures required for this study, as judged by the investigator.
  7. Enrolled in the Cystic Fibrosis Foundation Patient Registry.
  8. Clinically stable with no significant changes in health status within the 14 days prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  1. Use of any TCT within the 180 days prior to Visit 1.
  2. Any acute use of antibiotics (oral, inhaled or IV) or systemic within the 2 weeks prior to Visit 1 for lower respiratory tract symptoms.
  3. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4 weeks prior to Visit 1.
  4. Use of an agent within the 28 days prior to Visit 1.
  5. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1.
  6. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1.
  7. History of lung or liver transplantation, or listing for organ transplantation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
490 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Core

    Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).

06

What researchers measure

Primary outcomes

  1. Sweat Chloride at 6 months

    Change in sweat chloride from Baseline to 6 months.

    Time frame: 6 months

  2. Sweat Chloride at 30 months

    Change sweat chloride from Baseline to 30 months.

    Time frame: 30 months

  3. Forced expiratory volume at one second (FEV1) at 6 months

    Change in FEV1 from Baseline to 6 months.

    Time frame: 6 months

  4. Forced expiratory volume at one second (FEV1) at 30 months

    Change in FEV1 from Baseline to 30 months.

    Time frame: 30 months

Secondary outcomes

  1. Weight at 6 Months

    Change in weight from Baseline to 6 months.

    Time frame: 6 months

  2. Weight at 30 Months

    Change in weight from Baseline to 30 months.

    Time frame: 30 months

  3. BMI at 6 Months

    Change in BMI from Baseline to 6 months.

    Time frame: 6 months

  4. BMI at 30 months

    Change in BMI from Baseline to 30 months.

    Time frame: 30 months

  5. Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months

    Change in CFQ-R (respiratory domain) from Baseline to 6 months.

    Time frame: 6 months

  6. Cystic Fibrosis Questionnaire Revised (CFQ-R) at 30 months

    Change in CFQ-R (respiratory domain) from Baseline to 30 months.

    Time frame: 30 months

07

Study locations

56 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Stanford University Medical Center
    Palo Alto, California 94025, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Children's Healthcare of Atlanta and Emory University
    Atlanta, Georgia 30322, United States
  • Emory University
    Atlanta, Georgia 30327, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky
    Lexington, Kentucky 40506, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital, Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Wayne State University Harper University Hospital
    Detroit, Michigan 48201, United States
  • Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • The Minnesota Cystic Fibrosis Center
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Kansas City
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 69198, United States
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • The Cystic Fibrosis Center of Western New York
    Buffalo, New York 14203, United States
  • Cohen Children's Medical Center of New York
    Lake Success, New York 11042, United States
  • Northwell CF Center
    New York, New York 10021, United States
  • Children's Hospital of New York
    New York, New York 10032, United States
  • University of Rochester Medical Center Strong Memorial
    Rochester, New York 14642, United States
  • New York Medical College at Westchester Medical Center
    Valhalla, New York 10595, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Children's Hospital Medical Center of Akron
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospitals Case Medical Center/Rainbow Babies and Children's Hospital
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Cystic Fibrosis Program
    Cleveland, Ohio 44195, United States
  • Oklahoma Cystic Fibrosis Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Hershey Medical Center Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Intermountain Cystic Fibrosis Center
    Salt Lake City, Utah 84132, United States
  • University of Virginia
    Charlottesville, Virginia 22904, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. PubMed 34784492 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Dec 2024, 62 months.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's 62 months is above that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2019
First posted
Jul 30, 2019
StartActual
Oct 22, 2019
Primary completionActual
Dec 23, 2024
CompletionActual
Dec 23, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04038047
Lead sponsor
Nicole Hamblett
Collaborators
Cystic Fibrosis Foundation
Responsible party
Nicole Hamblett (Professor of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine Adjunct Professor, Biostatistics, University of Washington School of Medicine Co-Executive Director, Cystic Fibrosis Therapeutics Development, Seattle Children's Hospital) — Sponsor-investigator
First posted
Jul 30, 2019
Start date
Oct 22, 2019
Primary completion
Dec 23, 2024
Completion
Dec 23, 2024
Last update
Jan 28, 2025

Study contacts

Steven Rowe, MD
principal investigator · University of Alabama at Birmingham
David Nichols, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion